1. Osteoactivin is overexpressed in aggressively bone metastatic 4T1 subpopulations versus weakly bone metastatic breast cancer populations.
Osteoactivin is overexpressed in aggressively bone metastatic 4T1 subpopulations versus weakly bone metastatic breast cancer populations. A. The relative expression of osteoactivin (Agilent whole mouse genome microarray), expressed as the fold change relative to the parental 4T1 population. B. Northern blot analysis of in vivo selected, aggressively bone metastatic 4T1 subpopulations probed with osteoactivin and GAPDH as a loading control. Quantitative phosphorimager analysis was done and the values for osteoactivin were first normalized to GAPDH and then expressed relative to the 4T1 parental population. C. Immunoblot analysis of osteoactivin expression in weakly and aggressively bone metastatic breast cancer populations in culture. D. Immunoblot analysis of osteoactivin expression in primary tumor explants arising from mammary fat pad injection of parental 4T1 cells. Lysates from cultured 4T1 (4T1p) and bone metastatic (592 BM2) cells are included as negative and positive controls, respectively. The membranes in C and D were probed for α-tubulin as a loading control.
April A.N. Rose et al. Mol Cancer Res 2007;5:
©2007 by American Association for Cancer Research